Jacobs Levy Equity Management’s Tyra Biosciences TYRA Stock Holding History

Jacobs Levy Equity Management’s Portfolio TYRA Stock Details TYRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.85M	Sell	89,205 -72,999	-45%	-$2.42M	0.01%	528
2026 Q1	$6.21M	Buy	162,204 +32,451	+25%	+$1.05M	0.03%	381
2025 Q4	$3.41M	Sell	129,753 -121,809	-48%	-$2.24M	0.01%	488
2025 Q3	$3.52M	Sell	251,562 -143,737	-36%	-$1.64M	0.01%	490
2025 Q2	$3.78M	Buy	395,299 +93,498	+31%	+$888K	0.01%	503
2025 Q1	$2.81M	Buy	301,801 +57,556	+24%	+$745K	0.01%	586
2024 Q4	$3.4M	Buy	+244,245	New	+$4.43M	0.01%	498

Other funds holding TYRA

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

APMC

Alta Partners Management Company Jackson, Wyoming $127M AUM 230.85% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Jacobs Levy Equity Management's TYRA Position: Q2 2026 in Review

Jacobs Levy Equity Management reduced its Tyra Biosciences (TYRA) stake by 45% in Q2 2026, selling an estimated $2.42M and leaving 89,205 shares worth $2.85M. The position accounts for 0.01% of the portfolio, ranked #528.

Jacobs Levy Equity Management first reported a position in TYRA in Q4 2024 and has held it in 7 quarters since. The position peaked at $6.21M in Q1 2026. 168 funds tracked by Wall St. Rank hold TYRA as of Q2 2026.

Jacobs Levy Equity Management held 89,205 shares of Tyra Biosciences worth $2.85M as of Q2 2026.
Jacobs Levy Equity Management sold 72,999 Tyra Biosciences shares in Q2 2026, an estimated $2.42M.
Tyra Biosciences made up 0.01% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #528 holding.
Jacobs Levy Equity Management first reported a position in Tyra Biosciences in Q4 2024 and has held it in 7 quarters since.
Jacobs Levy Equity Management's Tyra Biosciences position peaked at $6.21M in Q1 2026.
168 funds tracked by Wall St. Rank held Tyra Biosciences as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.